Company Overview - TruBridge, Inc. (TBRG) focuses on providing technology solutions for the U.S. healthcare sector, particularly for small rural and community hospitals [2] - The company operates in two main segments: Financial Health, which includes revenue cycle management services, and Patient Care, which encompasses electronic health records and patient engagement platforms [2] Financial Performance - Financial Health now accounts for 64% of TruBridge's revenue and is identified as the company's growth engine [3] - The company has experienced significant impairments due to costly acquisitions, impacting performance and leading to all-time low share prices in 2023 [3] - Cash flow has improved through tighter working capital management and debt reduction, with leverage decreasing from 4.4x in 2024 to a manageable range of 2.5x–3x [4] Governance and Investment - New investors, including Pinetree Capital and Ocho Investments, now hold a combined 25% stake in TruBridge, prompting governance reforms such as annual board elections and the removal of the poison pill [3] - Improved governance and stronger financial discipline are seen as catalysts for a turnaround story for TruBridge [5] Strategic Focus - TruBridge is concentrating on expanding its Financial Health services while leveraging strong retention rates in Patient Care for cross-selling opportunities [4] - The company is also pursuing offshore operations to reduce costs and improve margins, targeting a 20% adjusted EBITDA [4] Market Outlook - Regulatory risks persist, particularly regarding potential funding changes related to Medicare and Medicaid, but stricter compliance requirements may increase demand for TruBridge's solutions [5] - The combination of governance reforms, financial discipline, and a clear margin expansion strategy positions TruBridge for potential upside [5]

Core Insights - Tempus AI stock experienced a significant 161% gain since the beginning of the year, but recently faced a decline following a well-known investor's decision to reduce her position in the stock [1][2] - The stock fell 12.4% from the end of last Friday's trading to the close of Thursday's market session [2] - Ark Invest reduced its position in Tempus AI by 62,352 shares, valued at approximately $5.2 million, impacting its weighting in the ARK Innovation ETF [4] Company Developments - Tempus AI received 510(k) clearance from the U.S. FDA for its RNA-based Tempus xR IVD device, aimed at supporting drug development programs [5] - Despite the reduction in the ARK Innovation ETF, Tempus AI remains the largest position in the ARK Genomic Revolution ETF, with a 10.7% weighting [5][6] Investor Sentiment - The reduction by Ark Invest may cause concern among investors, but the stock's significant position in the ARK Genomic Revolution ETF indicates continued support [6] - Ark Invest's trading strategy often involves buying and selling stocks, suggesting potential future purchases of Tempus AI if the stock price declines further [7]

BROSSARD, Quebec, Sept. 25, 2025 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using Artificial Intelligence (AI) technologies, announces the voting results of the annual meeting of the shareholders held earlier today. Mr. André Larente, Mr. Robert Dunn, Mr. Michael Braeuel and Mr. Philippe Couillard were elected as directors to hold office until the closing of the next annual meeting of t ...

Company Overview - PriceMDs.com, Inc. is an innovative healthcare technology and solutions company that significantly reduces medical costs for self-insured employers and their members [1][3] - The company provides a healthcare services marketplace platform that connects patients, physicians, surgery centers, and medical imaging facilities to deliver cost-effective medical care [3] - PriceMDs.com leverages cloud-based solutions to enable consumers and employers to access transparent pricing for surgeries, diagnostic imaging, and other healthcare procedures [3] Recent Developments - PriceMDs.com announced the entry into a senior secured credit facility of up to $20 million funded by BankUnited [1] - Roth Capital Partners acted as the exclusive financial advisor for this offering [1] Financial Partner Information - BankUnited is a national bank headquartered in Miami Lakes, Florida, providing a full range of consumer and commercial banking products and services [4] - BankUnited has a long-standing record of consistent operating performance and has been recognized as one of the top performing financial institutions in the country [6] Advisory and Legal Representation - Greenberg Traurig, LLP represented PriceMDs.com in the transaction [1] - Roth Capital Partners provides a full-service platform focused on serving growth companies and their investors [6]

Core Insights - NextGen Healthcare is partnering with Kno2 to enhance interoperability for healthcare organizations across the United States [1] - NextGen Healthcare has been a leader in interoperability for over a decade, focusing on cloud-based healthcare technology solutions [1] Company Overview - NextGen Healthcare is recognized as a leading provider of innovative, cloud-based healthcare technology solutions [1] - Kno2 is identified as the nation's largest healthcare communication network and a federally designated Qualified Health Information Network (QHIN) [1] Industry Impact - The collaboration aims to advance interoperability, which is crucial for improving communication and data exchange among healthcare organizations [1] - This partnership reflects a growing trend in the healthcare industry towards enhancing connectivity and efficiency through technology [1]

Core Insights - CareCloud, Inc. has launched Marketware, a physician relationship management and analytics platform aimed at enhancing hospital operations and financial performance [1][2] - The platform is designed to help hospitals strengthen physician alignment, optimize referral networks, and link engagement strategies to measurable growth [1][2] - Marketware has been integrated with CareCloud's AI Center of Excellence and other operational tools, creating new opportunities for hospitals to connect physician relationship data with financial performance [3] Company Overview - CareCloud provides a suite of AI and technology-enabled solutions that assist healthcare providers in improving financial and operational performance, streamlining clinical workflows, and enhancing patient experiences [5] - The company serves over 40,000 providers, focusing on reducing administrative burdens and operating costs while improving patient care [5] Market Impact - The implementation of Marketware has reportedly led to revenue increases for hospitals, with users expressing greater confidence in their financial and service growth initiatives [2] - The platform offers actionable intelligence for hospital executives, enabling them to track referral patterns, strengthen physician engagement, and support strategic planning [8]

Core Insights - Counterpart Health has introduced generative AI capabilities in its Counterpart Assistant (CA), enabling clinicians to interact with patient data in real time through AI chat, enhancing efficiency in patient care [1][2][3] - The new features allow CA to generate pre-visit summaries and provide actionable insights from over 100 data sources, helping physicians prepare better for patient visits [2][4] - This development is part of Counterpart Health's mission to transform value-based care through technology, aiming to reduce data overload and streamline clinical workflows [3][4] Company Overview - Counterpart Health is a subsidiary of Clover Health Investments, focused on AI-powered physician enablement, aiming to improve care delivery and patient outcomes [5] - The Counterpart Assistant platform is designed to help clinicians manage chronic conditions and deliver high-quality care, extending its benefits beyond Clover Health's Medicare Advantage plan [5] - The technology has shown positive impacts on managing various chronic diseases, including Diabetes and Chronic Kidney Disease, as evidenced by several published studies [5]

Cancer Startup Thyme Care Raises Funds at $1 Billion Valuation https://t.co/PKUkGEHJkY ...

Core Insights - Aclarion, Inc. has initiated the CLARITY trial to evaluate the clinical and economic value of its Nociscan technology in spine surgery for chronic low back pain [1][3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][4] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful lumbar discs [3][4] CLARITY Trial Details - The CLARITY trial is a prospective, randomized multi-center study involving 300 patients scheduled for surgical treatment of discogenic back pain [2][5] - The trial will randomize patients in a 1:1 ratio between surgeons blinded and unblinded to Nociscan results, with the primary endpoint being the change in back pain measured on a 100mm VAS scale at 12 months [2][5] - Initial patient enrollment has begun at the University of Miami Health System, with additional sites including Northwestern Medicine and Texas Back Institute [2][3] Market Context - Chronic low back pain affects an estimated 266 million people globally, representing a significant health challenge [3] - Aclarion aims for Nociscan to become the gold standard in identifying sources of low back pain through advanced diagnostic techniques [5][6]

Strive Asset Management is acquiring Semler Scientific at a $1.3 billion valuation, the company said on Monday, growing its Bitcoin holdings by snapping up a competitor that has come under pressure in a strategy that some analysts predict could become more common.  The Texas-based financial services firm, which was co-founded by Republican Ohio gubernatorial candidate Vivek Ramaswamy, said in a press release that it is acquiring Semler though an all-stock deal at $90.52 per share, while gaining 5,000 Bitcoi ...